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Background: The approval of sipuleucel-T in conjunction with data from other immunotherapeutic trials for prostate cancer and other
solid tumors demonstrates the potential of harnessing the patient's immune system for long-term survival. Thus, a range of therapeutic
approaches are under evaluation. This review describes the rationale for immunotherapy for prostate cancer, summarizes the approaches
under evaluation, and discusses sequencing options for immunotherapy in the current treatment paradigm.
Design: References for this review were identiﬁed through searches of PubMed with the search terms “prostate cancer,” “immune
system,” “vaccine,” “immunotherapy,” and “T cells.” Articles were also identiﬁed through searches of the authors' own ﬁles. The ﬁnal
reference list was generated based on originality and relevance.
Results: The immune system can recognize and respond to prostate tumor antigens, effected through tumor-associated antigens and
tumor inﬁltration of immune effector cells. However, evidence also suggests that prostate tumors are adept at escaping immunological
recognition, thus hypothesizing multiple therapeutic strategies. Therapeutic approaches could include vaccination and modulation of T-cell
function via the blockade of checkpoint receptors such as cytotoxic T-lymphocyte antigen-4 and programmed death 1. In phase III trials,
sipuleucel-T improved overall survival for an M1 patient population with castration-resistant prostate cancer and ipilimumab also did so
when given after radiotherapy in a subset of better risk patients. In randomized phase II trials, prostate-speciﬁc antigen-TRICOM improved
overall survival and tasquinimod improved progression-free survival.
Conclusion: Although immunotherapy has the potential to affect advanced prostate cancer, additional research is needed to (1) identify
predictive or surrogate markers of activity, (2) understand which agents are clinically effective alone or in combination with other therapies,
and (3) deﬁne the optimal timing for an immunotherapy to achieve maximal beneﬁt. r 2015 The Authors. Published by Elsevier Inc. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table 1
The immune system in prostate cancer [8–14]
Evidence of a protective immune response
Presence of effector T cells speciﬁc to TAAs [8]
Presence of effector T cells speciﬁc for epitopes on the androgen
receptor [9]
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Prostate cancer is the most common cancer among men
worldwide and a leading cause of cancer deaths among
them [1]. Early-stage prostate cancer can be managed with
an “active surveillance” approach, brachytherapy, external
beam radiotherapy (RT), and radical prostatectomy, with a
minority of patients eventually developing metastatic dis-
ease. Patients whose disease recurs after interventional
treatment or for those with de novo metastatic disease are
often treated with androgen deprivation therapy (ADT).
Disease that progresses despite ADT is referred to as
castration-resistant prostate cancer (CRPC). Until relatively
recently, the prognosis of patients with metastatic CRPC
(mCRPC) was poor, with a median survival for docetaxel-
based therapy of less than 2 years and no viable treatment
options for patients ineligible or progressing on or after
treatment with docetaxel [1].
During the past 3 years, progress has been made with
drugs such as cabazitaxel, abiraterone, enzalutamide, and
radium-223, thus improving the overall survival (OS) of
patients who were previously treated with docetaxel [1,2].
Abiraterone plus prednisone signiﬁcantly improved
progression-free survival (PFS) when compared with pre-
dnisone alone in chemotherapy-naïve patients with mCRPC
(16.5 vs. 8.3 mo; the median OS with abiraterone was not
reached after 22.2 mo of follow-up) [3], and sipuleucel-T
extends survival in men with asymptomatic or minimally
symptomatic mCRPC (25.8 vs. 21.7 mo with placebo) [4].
Results of an interim analysis from the phase III PREVAIL
trial were recently reported, showing a 29% reduction in the
risk of death with enzalutamide over placebo (Po 0.001)
in men with asymptomatic or mildly symptomatic
chemotherapy-naïve mCRPC [5].
Although metastatic prostate cancer is invariably a lethal
outcome, it offers multiple opportunities for therapeutic
intervention. Recent improvements in the understanding of
tumor-host interactions have led to numerous immunother-
apeutic approaches with the potential to complement, and
synergize with, other approved treatment modalities. This
review presents the rationale for using immunotherapy to
treat CRPC, summarizes recent clinical and trial progress,
and discusses sequencing strategies for immunotherapy
regarding CRPC treatment paradigms.Presence of antibodies against NY-ESO-1, a TAA [10]
NK cell tumor inﬁltration (potential protective role—correlated with a
lower risk of progression after ADT) [11]
Potential mechanisms of prostate cancer immune escape
Impaired NK cells (altered activating and inhibitory receptor proﬁles
and decreased cytolytic function) [12]
Increased levels of circulating and tumor-inﬁltrating immunosuppressive
Tregs (associated with a poorer prognosis) [13]
Inﬁltration of macrophages (after ADT) associated with an increased risk
of recurrence [11]
High PD-1 expression on tumor-inﬁltrating CD8 T-cells indicating
inactivity/exhaustion [14]
NK ¼ natural killer.2. Immune cells and the tumor microenvironment
The immune system's ability to respond to the biology of
neoplasia has been well documented. Cell types central to
the recognition and destruction of tumor cells include
macrophages/antigen-presenting cells (APCs), CD8þ cyto-
toxic T cells, and natural killer cells. Pathophysiologically,
tumors are adept at developing pathways to suppress
immune responses and escape from immune destruction,
culminating with evasion and clinical progression. Potentialmechanisms of evasion include the modulation of immune-
inhibitory (checkpoint) pathways to suppress T-cell activity
and the disruption of antigen processing and presentation.
Tumors can also recruit and promote the development of
immunosuppressive cell types, in particular regulatory T
cells (Tregs). Tumors may directly or indirectly mediate the
release of immunosuppressive factors, such as transforming
growth factor β and interleukin (IL)-10, which contribute to
the development of an immunosuppressive microenviron-
ment in and around the tumor [2,6].
As in other tumor types, clinical trial data have demon-
strated that the immune system can recognize and respond
to prostate cancer cells. Spontaneous or endogenous
immunity to prostate cancer cells is because of adaptive
as well as innate immunity. Indeed, data suggest that both
the innate and the adaptive immune systems are modulated
or dysregulated in patients with prostate cancer, which
thereby presents an opportunity to target multiple molecules
within immune regulatory pathways [2].
To understand the involvement of the immune system in
various tumor types, the presence of tumor-inﬁltrating cells
and their correlation with clinical outcomes is important.
For example, in advanced ovarian carcinoma, the duration
of OS and PFS was signiﬁcantly longer in patients with
tumor-inﬁltrating T cells [7]. Similar data have been
reported in a range of tumor types, including prostate
cancer, where although the data are more limited and
somewhat inconclusive, there is evidence to suggest that
the inﬁltration of prostate tumors by certain immune cells is
associated with prognosis (data are summarized in Table 1)
[8–14]. In a joint international initiative, several national
and international cancer and immunotherapy associations
have initiated a protocol for developing and validating an
immune score based on the type and the density of immune
cells in tumor inﬁltrates [15]. Initially evaluated in color-
ectal cancer, such “immune proﬁling” of the tumor immune
microenvironment appears to be one of the strongest
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Researchers are now evaluating whether immune proﬁling
may serve as a tool to help guide decision making and for
evaluating novel therapies, including immunotherapy, in
other solid tumor types, including prostate cancer. Hence,
immunotherapies are predicated on the potential to leverage
and amplify existing immune mechanisms (i.e., break
tolerization and stimulate apoptosis) and thus provide an
effective antitumor response.3. Immunotherapy treatment strategies for prostate
cancer
Considering the immune system's ability to respond to
prostate cancer antigens, a range of immunotherapeutic
strategies are being developed and evaluated with the goal
of inducing de novo or reactivating antitumor immune
responses or both. A key component to this strategy is to
overcome the mechanisms tumors use to escape detection
and destruction by the immune system. These escape
mechanisms are mediated by various factors including
immunosuppressive cells (e.g., Tregs), soluble factors
(e.g., tumor growth factor β1), and immune checkpoint
inhibitors (e.g., programmed death 1 [PD-1]) [6]. An
overview of the key complete and ongoing trials with
immunotherapies in mCRPC is provided in Tables 2 [4,16–
35] and 3, respectively.
3.1. Vaccines
“Vaccines” is a broad term encompassing various
approaches to elicit and enhance an immune response to
tumor-associated antigens (TAAs). Antitumor vaccines can
be generic (i.e., created or engineered to deliver selected
TAAs known to be immunogenic) or personalized (i.e.,
generated from the patient's own tumor-reactive immune
cells) (Table 2). Several prostate TAAs have been identiﬁed
that may form the basis of immunotherapeutic approaches
(Table 4) [10,36]. Of the peptide vaccines, prostate-speciﬁc
antigen (PSA)-TRICOM (PROSTVAC; Bavarian Nordic,
Kvistgaard, Denmark) has shown promising efﬁcacy and
tolerability in a phase II trial. Although there was no
improvement in PFS—the primary end point of the study
—and PSA responses were infrequent, the vaccine
improved OS when compared with placebo (25.1 vs.
16.6 mo, P = 0.006) [16]. It is unclear whether the OS
beneﬁt reported in the absence of a PFS improvement or
responses is because of the unique patterns of response
reported with some immunotherapies (as discussed in
Section 4.2) or because of a confounding factor, as has
been proposed as occurring in the sipuleucel-T Immuno-
therapy for Prostate Adenocarcinoma Treatment (IMPACT)
(discussed later) [37]. Nevertheless, these data led to the
opening of the phase III PROSPECT trial (NCT01322490)
to evaluate whether PSA-TRICOM, with or withoutgranulocyte-macrophage colony-stimulating factor (GM-
CSF), can prolong survival in chemotherapy-naïve patients
with mCRPC. PSA-TRICOM is also being studied in a
phase II trial (NCT01145508) as an add-on to a chemo-
therapy doublet of docetaxel with prednisone (Table 4).
However, thorough analysis of data from these ongoing
trials is needed to demonstrate unequivocally that any
beneﬁt is because of the vaccine.
Personalized peptide vaccine (PPV), an approach that
“screens” patients for their immunoreactivity against a panel
of epitopes from TAAs before vaccinating them with up to
4 peptides to which they had reacted most strongly,
improved PFS when added to low-dose estramustine
therapy (Table 2) [17]. PPV plus low-dose estramustine
was well tolerated and increased levels of immunoglobulin
G (IgG) and cytotoxic T-cell responses to the vaccinated
peptides. A prospective cohort trial comparing PPV in
patients in whom treatment with docetaxel had failed and
patients who had not received docetaxel showed a signiﬁ-
cant survival beneﬁt for the latter group (Table 2), and there
was a nonsigniﬁcant survival beneﬁt of 7.3 months (17.8
[95% CI: 14.9–20.6] vs. 10.5 [95% CI: 7.1–14.0]) for PPV-
treated patients in whom previous treatment with docetaxel
had failed when compared with matched historical controls
who did not receive PPV [18].
Vaccines based on nucleic material from TAAs have also
been studied in prostate cancer. For example, DNA vaccine
pTVG-HP has produced immunological responses in
patients with recurrent, localized prostate cancer and some
evidence of clinical responses (Table 2) [19]. Of 8 patients
who had aZ200% increase in PSA doubling time, 6 had
detectable long-term prostatic acid phosphatase–speciﬁc
interferon-γ–secreting T-cell responses [36]. An ongoing
phase II trial (NCT00849121) evaluating the immunoge-
nicity of pTVG-HP with GM-CSF as an adjuvant is
ongoing. CV9103 (RNActive; CureVac GmbH, Tübingen,
Germany), an RNA vaccine encoding for PSA, prostate
stem cell antigen, prostate-speciﬁc membrane antigen, and
six transmembrane epithelial antigen of the prostate 1, was
safe and well tolerated in a phase I/IIa study and had
encouraging signs of clinical efﬁcacy (Table 2) [20]. A
phase IIb trial is ongoing (NCT01817738).
Another type of anticancer vaccine was derived from
whole tumor cells modiﬁed genetically to coexpress another
molecule, an adjuvant such as GM-CSF. GVAX, a whole-
cell vaccine expressing GM-CSF, had shown promising
clinical activity in phase I when combined with ipilimumab,
a fully human monoclonal antibody against cytotoxic
T-lymphocyte antigen-4 (CTLA-4) (Table 2) [33]. How-
ever, 2 phase III trials using GVAX alone and in combi-
nation with docetaxel were stopped early because of a lack
of efﬁcacy and increased mortality [38,39].
A growing area of interest is the use of “cell-based
vaccines” made from a patient's own APCs and precursors,
which are activated ex vivo with TAA and reinfused into
the patient. The best known of these is sipuleucel-T, which
Table 2
Immunotherapeutic treatment strategies for prostate cancer [4,16–35]
Agent(s) Description Key studies Key outcomes Reference
Peptide vaccines
PSA-TRICOM (PROSTVAC) PSA þ 3 T-cell costimulatory
molecules (B7-1, LFA-3,
and ICAM-1)
A phase II RCT in 125 patients
with mCRPC randomized 2:1 to
receive 1 priming dose (2  108
pfu) and 6 booster doses
(1  109 pfu) of PSA-
TRICOM þ GM-CSF or control
vector þ saline injections
Patients receiving PSA-TRICOM had longer median OS by
8.5 mo (25.1 vs. 16.6 for controls; HR = 0.56, 95%
CI: 0.37–0.85, P = 0.006) and better 3-y survival rates (25/82
[30%] vs. 7/40 [17%])
Kantoff et al. [16]
Personalized peptide vaccine
(PPV)
Vaccine prepared withr4
peptides according to each
patient's immunoreactivity
proﬁle; peptides derived
from various TAAs
(including PSA, PAP,
PSMA, and MDRP)
A phase II trial in 57 patients with
CRPC randomized to treatment
with PPV and either low- or
standard-dose EMP (280 vs.
560 mg/d, respectively)
PPV/low-dose EMP: 6/27 patients (21%) PR; 15/27 patients
(54%) SD as best responses
Noguchi et al. [17]
PPV/standard-dose EMP: 6/28 patients (20%) PR; 8/28 patients
(28%) SD as best responses
Median PFS was 8.5 mo (95% CI: 4.7–8.8) vs. 2.8 mo for
PPV/low-dose EMP vs. PPV/standard-dose EMP, respectively
(HR ¼ 0.28, 95% CI: 0.14–0.61, P ¼ 0.001)
Median OS was undeﬁned (95% CI: 11.7–17.4) vs. 16.1 mo (95%
CI: 8.0–13.4) for PPV/low-dose EMP vs. PPV/standard-dose
EMP, respectively (HR ¼ 0.30, 95% CI: 0.10–0.91, P ¼
0.033)
A phase II open-label study
comparing PPV in 20 patients in
whom treatment with docetaxel
had failed and 22 patients who
had not received docetaxel
Median OS was 14  8 mo (95% CI: 9.7–20.0) for PPV after
treatment with docetaxel vs. not reached within 22 mo
for PPV without treatment with docetaxel (HR ¼ 0  38, 95%
CI: 0.13–1.13, P ¼ 0.081)
Noguchi et al. [18]
DNA/RNA vaccines
pTVG-HP PAP vaccine PAP-encoding plasmid DNA A phase I/IIa single-arm, dose-
escalation study (100, 500, or
1,500 μg) in 22 patients with
recurrent stage D0 prostate
cancer receiving pTVG-HP
coadministered with GM-CSF 6
times at 14-d intervals
Immunological responses: 6/22 patients (27.3%, 95% CI: 13.1–
48.2) developed at least a 3-fold increase in PAP-speciﬁc CD4þ
proliferative T cells, and 3/22 patients (13.6%, 95% CI: 4.7–
33.3) developed at least a 3-fold increase in CD8þ proliferative
T cells
McNeel et al. [19]
Clinical responses: 7/22 patients experienced at least a doubling of
the PSA doubling time; median increase in PSA doubling time
from the pretreatment to the on-treatment period was 1.3 mo
(4.4–24.0 mo, P ¼ 0.033)
CV9103 (RNActive) PSA, PSCA, PSMA, and
STEAP1 as self-adjuvanted
full-length mRNAs
A phase I/IIa single-arm, dose-
escalation study (256, 640, or
1,280 mg total mRNA) in 44
patients with CRPC (480%
mCRPC) with increasing PSA
levels received CV9103 at 1, 3,
7, 15, and 23 wk
Immunomonitoring performed in 33/38 patients in the high-dose
cohort; induction of antigen-speciﬁc T cells in 79% of patients,
more than half of whom developed immune responses to42
antigens
Kübler et al. [20]
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Cell-based vaccines
Sipuleucel-T Autologous PBMCs (including
APCs) activated ex vivo with
a recombinant fusion protein
(PA2024) comprising PAP
fused to GM-CSF
A phase III RCT (IMPACT) in 512
men with mCRPC randomized
2:1 to receive sipuleucel-T or
placebo Q2W for 3 infusions;
OS was the primary end point
Patients receiving sipuleucel-T had a relative reduction in risk of
death of 22.0% (P ¼ 0.03) vs. placebo (HR ¼ 0.78, 95% CI:
0.61–0.98); this represented a 4.1-mo improvement in median
OS (25.8 mo) vs. placebo (21.7 mo)
Kantoff et al. [4]
There was no effect of treatment on objective or clinical TTP
Sipuleucel-T was well tolerated; infusional AEs, including fever/
chills, mainly grade 1/2
A phase III RCT in 127 men with
asymptomatic mCRPC
randomized 2:1 to receive
sipuleucel-T or placebo every
2 wk for 3 infusions; TTP was
the primary end point
TTP did not improve signiﬁcantly after sipuleucel-T; 11.7 wk
(95% CI: 9.1–16.6) vs. 10.0 wk (95% CI: 8.7–13.1) for placebo
(HR ¼ 1.45, 95% CI: 0.99–2.11, P ¼ 0.052)
Small et al. [21]
Possible survival advantage after treatment with sipuleucel-T; median
OS was 25.9 mo (95% CI: 20.0–31.9) vs. 21.4 mo (95% CI: 12.3–
25.8) for placebo (HR ¼ 1.70, 95% CI: 1.13–2.56, P ¼ 0.01)
In a patient subset, median ratio of T-cell stimulation index at
8 wk was approximately 8-fold higher vs. preinfusion after
treatment with sipuleucel-T (16.91 vs. 1.99, P ¼ 0.001)
Treatment was well tolerated; rigors (59.8% vs. 8.9%) and pyrexia
(29.3% vs. 2.2%) for treatment vs. placebo, respectively, were
the most common AEs, both primarily infusion reactions
Sequential phase I and II trials to
determine the safety, efﬁcacy, and
capacity to break immune tolerance
to PAP in 31 patients with
mCRPC who received sipuleucel-T
for 3 infusions every 4 wk; patients
improving or with SD had a fourth
infusion in week 24
There was a450% decrease in PSA level in 3 patients, and
another 3 had 25%–49% decreases in PSA levels
Small et al. [22]
Of 26 patients, 10 (38%) developed immune responses to PAP
Median TTP: 34 wk for patients who developed immune response
(n ¼ 20) vs. 13 wk for patients who did not (n ¼ 11); P ¼
0.027
Treatment was well tolerated; fever was the most common AE,
after 15 infusions (14.7%)
DCVAC/Pa Dendritic cells pulsed with
killed LNCap prostate
cancer cell line
A phase I/II trial using DCVAC/Pa
for patients with biochemical
failure after prostatectomy or
primary radiotherapy. Patients
received 12 doses of vaccine at
4-wk intervals
Of 20 treated patients, all had a signiﬁcantly prolonged PSA
doubling time; 7 had stable PSA levels during the treatment.
Mean PSA doubling time increased from 8.15 mo before
therapy to 52.64 mo after 12 doses (Po 0.0015). Treatment
did not lead to any signiﬁcant side effects
Spisek et al. [23]
T-cell modulators
Ipilimumab Fully human monoclonal
antibody against CTLA-4
with chemotherapy
A phase I study of a single, 3 mg/
kg dose of ipilimumab in 14
patients with mCRPC
There was aZ50% decrease in PSA level in 2 patients; treatment
was well tolerated
Small et al. [24]
Ipilimumab following
radiotherapy
As above A phase III trial comparing
ipilimumab vs. placebo
following radiotherapy in
patients with mCRCP previously
treated with docetaxel
The primary end point was not met (OS: ipilimumab, 11.2 mo;
placebo, 10.0 mo; HR ¼ 0.85; P ¼ 0.053); the safety proﬁle
was consistent with prior studies. Post hoc subgroup analysis
showed that ipilimumab improved OS in patients with a better
prognostic proﬁle (median OS: ipilimumab [n ¼ 146],
22.7 mo; placebo, 15.8 mo [n ¼ 142])
Kwon et al. [25]
Ipilimumab with GM-CSF As above, with adjuvant A phase I study of ipilimumab (0.5–
10 mg/kg on day 1 of each 28-d
cycle  6) with GM-CSF (250 μg/
m2/d) on days 1–14 of each 28-d
cycle in 36 patients with mCRPC
Of 6 patients treated at 3 mg/kg, 3 (50%) had conﬁrmed decreases
in PSA levels ofZ50%, with TTP of 22, 26, and 103 wk; 1
patient had a PR in hepatic metastases
Harzstark et al. [26]
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Table 2
Continued
Agent(s) Description Key studies Key outcomes Reference
Other immunomodulators
Tasquinimod Quinoline-3-carboxamide
with antiangiogenic and,
potentially,
immunomodulatory
activity
Phase I, dose-escalation studies in
patients with chemotherapy-
naïve CRPC. Patients (n ¼ 32)
received tasquinimod for up to
1 y at ﬁxed doses of 0.5 or
1.0 mg/d, or an initial dose of
0.25 mg/d that was escalated to
1.0 mg/d
The maximum tolerated dose was 0.5 mg/d, but using intrapatient
dose escalation, 1.0 mg/d was well tolerated. DLT was sinus
tachycardia and asymptomatic amylase elevation
Bratt et al. [27]
There was aZ50% decrease of PSA levels in 2 patients, and the
median time to PSA progression (425%) was 19 wk. Of 15
patients, 3 developed new bone lesions on study (median time
on study 34 wk)
A randomized, phase II study
comparing tasquinimod
(0.25 mg/d escalating to 1.0 mg/
d over 4 wk) and placebo in men
with chemotherapy-naïve,
minimally symptomatic mCRPC
(n ¼ 134 in tasquinimod arm; n
¼ 67 in placebo)
The 6-mo progression-free proportions were 69% and 37% in the
tasquinimod and placebo arms, respectively (Po 0.001).
Median PFS was 7.6 vs. 3.3 mo (P ¼ 0.0042)
Pili et al. [28]
AEs that were more frequent in the tasquinimod arm included
gastrointestinal disorders, fatigue, musculoskeletal pain, and
elevations of pancreatic and inﬂammatory biomarkers. The
incidence of grade 3/4 adverse events was 40% with
tasquinimod vs. 10% with placebo
Lenalidomide Oral thalidomide analogue
with antiangiogenic and
immunomodulatory
properties
A phase II, single-institution study
of lenalidomide in patients with
chemotherapy-naïve CRPC.
Patients (n ¼ 32) received
lenalidomide orally (25 mg/d)
for 21 d in 28-d cycles
The rate of clinical beneﬁt (SD/CR/PR) was 63%, the median time
to radiographic progression was 4 mo, and median OS was
20 mo. Of 27 PSA-evaluable patients, 13 (48%) had a decrease
in PSA level and 3 patients (11%) had a decrease ofZ50%
Nabhan et al. [34]
Grade 3/4 hematologic toxicities were the most common AEs.
Serious AEs occurred in 14 patients (44%), including 1 patient
with a rash deﬁnitely related to lenalidomide
Multimodal combinations
Ipilimumab with or without
docetaxel
As above A randomized, phase II study
comparing ipilimumab (3 mg/kg
every 4 wk for 4 cycles) alone
(A) or with 1 dose of docetaxel
(B; 75 mg/m2 on day 1) in 43
chemotherapy-naïve patients
with CRPC
Coadministration of docetaxel did not enhance activity: 6 patients
(3 in each arm) had a decrease of450% in PSA levels; 3
patients (2 in arm A and 1 in arm B) had conﬁrmed PSA
responses (79þ, 169þ, and 280 d)
Small et al. [29]
There were no radiologic responses with PSA responses
Of 43 patients, 36 (84%) hadZ1 AE related to ipilimumab; the
most common included fatigue (44%) and pruritus (26%)
Of 43 patients, 3 (6%) experienced an immune breakthrough event
Ipilimumab with ADT Fully human monoclonal
antibody against CTLA-4
with ADT
A randomized, phase II study
comparing a single dose of
ipilimumab (3 mg/kg) with
ADT, with ADT only, in 108
patients with advanced prostate
cancer; on progression, those in
the latter group were allowed to
cross over to the ipilimumab
group
Patients receiving ipilimumab with ADT were more likely to have
undetectable PSA levels by 3 mo (55% vs. 38%)
Tollefson et al. [30]
Some patients treated with ipilimumab had signiﬁcant clinical
response and disease downstaging
Of the patients treated with ipilimumab, 15 (27.7%) had cutaneous
changes, including localized vitiligo and previously unreported
desquamation of atypical nevi
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Ipilimumab with or without
RT
Fully human monoclonal
antibody against CTLA-4
with/without RT
A phase I/II study to assess safety of
ipilimumab (3, 5, or 10 mg/kg
every 3 wk for 4 cycles) alone or
with RT at 3 or 10 mg/kg in 71
patients with mCRPC with/
without prior chemotherapy;
single-dose RT (8 Gy/lesion, up
to 3 lesions per patient) given 24–
48 h before ﬁrst ipilimumab dose
Of 28 tumor-evaluable patients receiving 10 mg/kg of
ipilimumab  RT, 1 had CR and 6 had SD
Slovin et al. [31]
No DLTs; treatment-related AEs and irAEs common across all
cohorts with or without RT; irAEs generally responsive to
immunosuppressives
Ipilimumab with PSA-
TRICOM
Fully human monoclonal
antibody against CTLA-4
with peptide vaccine
A phase I dose-escalation trial
assessing safety/tolerability of
ipilimumab (1, 3, 5, or 10 mg/kg
every month starting at day 15)
with PSA-TRICOM (2  108
pfu day 1 then booster doses of
1  109 pfu every month
starting at day 15) in 30 patients
with mCRPC
In 24 chemotherapy-naïve patients, median OS was not reached at
publication, and 3-y OS was 52.6% (range: 31.4–72.9); 6
patients with prior chemotherapy had median OS of 31.3 mo
(range: 4.8–41.4) and 3-y OS of 16.7% (range: 3.0–56.4)
Madan et al. [32]
Of 6 patients who received prior chemotherapy, 1 had PSA level
decrease from baseline; 14/24 patients (58%) in 3.0-, 5.0-, and
10.0-mg/kg cohorts who were chemotherapy naïve had a PSA
level decrease; 6 (25%) had450% decrease
AEs were primarily local grade 1/2 injection-site reactions and
irAEs (most commonly rash)
No DLTs; combination not associated with increased irAEs
compared with ipilimumab alone
Ipilimumab and GVAX Fully human monoclonal
antibody against CTLA-4
with irradiated allogeneic
prostate cancer cells
engineered to produce GM-
CSF
A phase I dose-escalation trial
using 1 GVAX priming dose
(5  108 cells) with subsequent
booster doses (3  108 cells)
every 2 wk for 24 wk combined
with ipilimumab (0.3, 1.0, 3.0,
or 5.0 mg/kg) every 4 wk in 28
patients with mCRPC
The 3.0-mg/kg ipilimumab cohort expanded because of serious
toxicity/DLT in the 5.0-mg/kg cohort; treatment otherwise
tolerable
van den Eertwegh
et al. [33]
Of 28 patients, 7 (25%) had450% decrease in PSA levels
No PSA responses in the 0.3-/1.0-mg/kg cohorts but 5 of 22
patients (23%) in the 3.0-/5.0-mg/kg cohorts had a conﬁrmed
PSA PR (450% decrease from baseline); all patients with an
irAE had PSA PR
Median OS of all patients was 29.2 mo; patients who developed
PSMA-speciﬁc antibody responses had longer median OS than
patients who did not (46.5 mo [95% CI: 30.2–62.8] vs. 20.6 mo
[95% CI: 19.0–22.2]; P ¼ 0.028); 15 patients had SD
(duration: 3–27 mo)
Lenalidomide and GM-CSF Oral thalidomide analogue
with an immunostimulatory
cytokine
A phase I/II trial in patients with
CRPC who has not received
prior immunotherapy or
chemotherapy (n ¼ 32). All
patients received 250 ug of GM-
CSF given subcutaneously 3
times weekly with lenalidomide
given orally 25 mg/d on days 1–
21 of a 28-d cycle
The response rate among the 11 evaluable patients was 18%; 81%
of patients had a decrease in PSA level, but this was
onlyZ50% in 4 patients
Garcia et al. [35]
The most common grade 1 and 2 AEs included fatigue (69% of
the patients), nausea/vomiting (34%), and diarrhea (28%).
Grade 3 or 4 AEs occurred in 22% of the patients and were
primarily thrombocytopenia (9%) or neutropenia (19%) or both
AEs ¼ adverse events; CR ¼ complete response; DC ¼ dendritic cell; DLT ¼ dose-limiting toxicity; EMP ¼ estramustine phosphate; HR ¼ hazard ratio; ICAM-1 ¼ intercellular adhesion molecule-1;
IMPACT ¼ Immunotherapy for Prostate Adenocarcinoma Treatment; irAE ¼ immune-related adverse event; LFA-3 ¼ leukocyte function–associated antigen-3; MDRP ¼ multidrug resistance protein;
mRNA ¼ messenger RNA; PAP ¼ prostatic acid phosphatase; PBMCs ¼ peripheral blood mononuclear cells; pfu ¼ plaque-forming units; PR ¼ partial response; PSCA ¼ prostate stem cell antigen;
PSMA ¼ prostate-speciﬁc membrane antigen; Q2W ¼ every 2 wk; RCT ¼ randomized controlled trial; SD ¼ stable disease; STEAP1 ¼ six transmembrane epithelial antigen of the prostate 1; TTP ¼ time
to progression.
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Table 3
Selected ongoing studies of immunotherapy in prostate cancer
Therapy Phase Description Study identiﬁer Latest statusa
Vaccines
PSA-TRICOM with or without
GM-CSF
III An RCT evaluating efﬁcacy in asymptomatic/
minimally symptomatic patients with mCRPC
NCT01322490 Recruiting; estimated study completion
date, August 2016
Primary outcome: OS
Secondary outcomes: proportion of event-free
patients vs. placebo
pTVG-HP with GM-CSF II A randomized, open-label, 2-arm study comparing
different dosing schedules (one schedule
adaptable based on immune responses) in patients
with nonmetastatic CRPC
NCT00849121 Ongoing; estimated study completion
date, September 2014
Primary outcomes: safety and immune responses
Secondary outcomes: PSA doubling time and 1-y
metastasis-free survival
Sipuleucel-T with pTVG-HP
DNA booster vaccine
II An open-label, randomized, efﬁcacy study in
patients with mCRPC
NCT01706458 Recruiting; estimated study completion
date, June 2015
Primary outcome: immune response
Secondary outcomes: PFS, TTP, and PSA doubling
time
Mixed 20 peptides vaccine I An exploratory randomized, open-label, dose-
ranging study in patients with CRPC
UMIN000008209 Recruitment completed
Primary outcome: safety
Secondary outcomes: immune responses/minimum
immunological effective dose and PSA responses
T-cell modulators
Ipilimumab III An RCT in chemotherapy-naïve patients with
asymptomatic/minimally symptomatic mCRPC
comparing ipilimumab with placebo
NCT01057810 Ongoing; estimated study completion
date, February 2016
Primary outcome: OS
Secondary outcomes: PFS, time to pain progression,
time to subsequent nonhormonal systemic
therapy, and safety
Ipilimumab with or without
GM-CSFb
II A randomized, open-label study in chemotherapy-
naïve patients with mCRPC
NCT01530984 Not yet recruiting; estimated study
completion date, December 2018
Primary outcomes: PSA response, PSA decrease
Secondary outcomes: duration of PSA response,
time to PSA progression, frequency of immune
toxicities, T-cell activation, and objective
responses
Ipilimumab with GM-CSFb I An open-label, single-arm, dose-escalation study in
patients with mCRPC
NCT00064129 Ongoing
Primary outcome: MTD that results in that results
ino33% DLT
Secondary outcomes: adaptive immunity, PSA and
objective responses, safety, anti-idiotype
antibody, and PK
AMG-212—T-cell–engaging,
bispeciﬁc antibody
I A ﬁrst-in-man, open-label, single-arm, dose-
escalation study
NCT01723475 Recruiting; estimated study completion
date, December 2015
Primary outcomes: safety and MTD
Secondary outcomes: PK, tumor responses, and PSA
responses
Other immunomodulators
Tasquinimod III A randomized, placebo-controlled study of
tasquinimod in men with mCRPC
NCT01234311 Ongoing; estimated study completion
date, January 2016
Primary outcome: PFS
Tasquinimod II A randomized, proof-of-concept study of
maintenance tasquinimod in patients with
mCRPC who are not progressing after ﬁrst-line,
docetaxel-based chemotherapy
NCT01732549 Recruiting; estimated study completion
date, February 2016
Primary outcome: radiologic PFS
Secondary outcomes: OS, TTP on next therapy,
symptomatic PFS, and safety
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Continued
Therapy Phase Description Study identiﬁer Latest statusa
Lenalidomide I/II A randomized study of 2 different doses of
lenalidomide in biochemically relapsed patients
with prostate cancer (M0) after local treatment
NCT00348595 Ongoing; estimated study completion
date, July 2015
Primary outcomes: safety, tolerance, and rate of PSA
progression
Secondary outcome: effects on PSA constructs
Multimodal combinations
Enzalutamide with or without
PSA-TRICOM
II A randomized trial combining vaccine therapy and
enzalutamide in patients with mCPRC
NCT01867333 Ongoing; estimated ﬁnal collection date
for primary outcome, June 2016
Primary outcome: TTP
Secondary outcomes: OS, time to PSA progression,
and immune response
PSA-TRICOM with docetaxel
and prednisone or docetaxel
and prednisone alone
II A randomized, open-label study in patients with
mCRPC comparing chemotherapy with or without
vaccine
NCT01145508 Ongoing; estimated ﬁnal collection date
for primary outcome, June 2013
Primary outcome: OS
Secondary outcomes: TTP, ORs, PSA responses,
and immune responses before/after docetaxel;
association between PSA-speciﬁc immune
responses, TTP, and OS, association between
predicted and actual survival
Sipuleucel-T with indoximod II An RCT in patients with mCRPC evaluating
addition of IDO inhibitor (indoximod 1,200 mg/d
in 2 doses) to vaccine therapy
NCT01560923 Recruiting; estimate study completion
date, July 2015
Primary outcome: immune response to vaccine
Secondary outcomes: TTP, PFS, ORR, OS, and QoL
Sipuleucel-T with enzalutamide II Sipuleucel-T with concurrent or sequential
enzalutamide in patients with mCRPC
NCT01981122 Ongoing; estimated ﬁnal collection date
for primary outcome, September 2015
Primary Outcome: PA2024-speciﬁc T-cell immune
response to sipuleucel-T over time
Secondary outcomes include time to PSA
progression, OS, and safety
Sipuleucel-T with abiraterone
acetate and prednisone
II Sipuleucel-T with concurrent or sequential
abiraterone acetate plus prednisone (starting next
day after ﬁrst vaccine infusion or 6 wk after last
vaccine infusion, respectively) in patients with
mCRPC
NCT01487863 Ongoing; estimated ﬁnal collection date
for primary outcome, July 2015
Primary outcome: immune response to vaccine
(APC activation)
Secondary outcomes: immune response (various
parameters); safety
Sipuleucel-T and ipilimumab
given immediately or
delayed
II A randomized trial to determine the effects of
ipilimumab, as an immediate or delayed
treatment, following completion of sipuleucel-T
in patients with mCRPC
NCT01804465 Active; estimated study completion date,
December 2016
Primary outcome: safety and effect of the timing of
ipilimumab administration on sipuleucel-T
immune responses
Sipuleucel-T and ipilimumab I A phase I trial in patients with advanced CRPC NCT01832870 Recruiting; estimated study completion
date, December 2015
Primary outcome: antigen-speciﬁc memory T-cell
response, antigen-speciﬁc memory T-cell
proliferation, and antibody responses against
PA2024 and PAP
GVAX with low-dose
cyclophosphamide and
degarelix acetate, or
degarelix acetate alone
I/II A randomized, open-label study in neoadjuvant
setting in patients with high-risk localized prostate
cancer
NCT01696877 Recruiting; estimated study completion
date October 2015
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Continued
Therapy Phase Description Study identiﬁer Latest statusa
Primary outcomes: CD8þ T-cell inﬁltration into the
prostate, safety, and tolerability
Secondary outcomes: CD4þ T-cell and Treg
inﬁltration into the prostate and their ratio, tissue
androgen concentrations/AR expression, markers
of apoptosis in prostate tissue, pathological CR,
antibodies to prostate-associated antigens, PSA
response rate, and time-to-PSA-recurrence
Ipilimumab with abiraterone
acetate and prednisone
I/II An open-label, single-group study in chemotherapy
and immunotherapy-naïve patients with
progressive mCRPC
NCT01688492 Recruiting; estimated study completion
date, September 2015
Primary objectives: safety and PFS
Secondary objectives: PSA kinetics, measurable
disease, and radionuclide bone scan
Ipilimumab with leuprolide
acetate
II An open-label, single-arm study in a neoadjuvant
setting in patients with high-risk localized prostate
cancer
NCT01194271 Recruiting; estimated ﬁnal collection date
for primary outcome, September 2015
Primary outcome: immunological measures
Ipilimumab with leuprolide,
goserelin, or degarelix
II An open-label study in patients with castration-
sensitive prostate cancer
NCT01377389 Recruiting; estimated study completion
date for primary outcome, June 2016
Primary outcomes: proportion of patients achieving
PSA level ≤0.2 ng/ml at the seventh month
Ipilimumab with leuprolide
acetate, bicalutamide, or
ADT alone
II A randomized, open-label, crossover study
comparing ipilimumab with concurrent androgen
ablative therapy with an initial phase of ADT
alone in patients with CRPC/mCRPC
NCT00170157 Completed, November 2010
Primary outcome: proportion of patients remaining
progression free
Secondary outcome: initial PSA response
CT-011 with sipuleucel-T or
with sipuleucel-T and low-
dose cyclophosphamide
II A randomized, open-label pilot study in patients
with chemotherapy-naïve mCRPC
NCT01420965 Recruiting; estimated study completion
date, December 2017
Primary outcome: feasibility and immune efﬁcacy
Secondary outcomes: PFS and OS
Lenalidomide with
bevacizumab, docetaxel, and
prednisone
II Trial using bevacizumab, lenalidomide, docetaxel,
and prednisone in patients with CPRC
NCT00942578 Ongoing; estimated study completion
date, July 2015
Primary outcome: safety
Secondary outcomes: OS
Lenalidomide plus paclitaxel I/II A modular trial using lenalidomide and paclitaxel in
patients with CRPC and lymph node–dominant
metastases
NCT00933426 Ongoing; estimated study completion
date, August 2016
Primary outcome: MTD
Secondary outcomes: PFS
AR ¼ androgen receptor; CR ¼ complete response; DLT ¼ dose-limiting toxicity; IDO ¼ indoleamine 2,3-dioxygenase; MTD ¼ maximum tolerated
dose; OR ¼ objective response; ORR ¼ objective response rate; PK ¼ pharmacokinetics; QoL ¼ quality of life; RCT ¼ randomized controlled trial;
TTP ¼ time to progression.
aPer http://clinicaltrials.gov July 2014.
bGiven as an adjuvant.
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the US Food and Drug Administration. In the landmark
phase III Immunotherapy for Prostate Adenocarcinoma
Treatment study, sipuleucel-T prolonged survival in men
with asymptomatic or minimally symptomatic mCRPC
(hazard ratio = 0.78, 95% CI: 0.61–0.98) but had no effect
on time to progression [4]. Despite the approval of
sipuleucel-T based on these data, concerns were raised that
the survival beneﬁt reported in the trial, which was notaccompanied by evidence of a measurable antitumor effect,
may be because of either an imbalance in unmeasured
prognostic variables or a ﬂaw in the trial design [37].
A potentially relevant factor that has been proposed is the
different treatment of cells harvested from patients in the
placebo arm compared with those in the sipuleucel-T arm.
In the placebo arm, two-thirds of the cells harvested were
frozen and not reinfused; this large cell loss could have had
a detrimental effect on patient survival, potentially
Table 4
TAAs as targets for future prostate cancer vaccines [10,36]
TAA Description
Prostate stem cell antigen Expressed in a subset of basal and secretory cells in normal prostate and overexpressed in CRPC and bone metastatic
prostate cancers
Prostate cancer membrane antigen Abundantly expressed at all stages of disease and up-regulated in CRPC and mCRPC
MUC-1 Overexpression of MUC-1 has been related to tumor angiogenesis, proliferation, metastasis, and immunosuppression.
Expression of MUC-1 appears different in normal, benign, and cancerous prostate tissues, although further
evaluation is needed
uPA and its receptor The uPA system has a key role in angiogenesis, cancer invasion, and metastasis; it has been strongly associated with
prostate cancer metastasis. uPA plasma levels are higher in men with prostate cancer than in normal controls and are
reported to be increased in patients with metastatic vs. nonmetastatic disease
EMMPRIN EMMPRIN can modulate the tumor microenvironment by inducing angiogenic factors and regulating the growth and
survival of tumor cells. Data suggest that EMMPRIN has a crucial role in prostate cancer progression
Epidermal growth factor receptor
(EGFR)
Increased EGFR expression has been reported for many tumor types. Studies in prostate cancer also showed increased
expression, with an association between EGFR expression and tumor progression or the development of androgen
independence. Additionally, EGFR overexpression has been associated with an increased rate of relapse after therapy
Platelet-derived growth factor
receptor (PDGFR)
PDGFR is expressed by many primary and metastatic prostate tumors and across various stages of disease
NY-ESO-1 NY-ESO-1 is widely expressed by cancers and may elicit spontaneous humoral and cellular immune responses
EMMPRIN = extracellular matrix metalloproteinase inducer protein; MUC-1 = mucin-1; uPA = urokinase plasminogen activator.
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The alternative explanations proposed for the outcome of
the Immunotherapy for Prostate Adenocarcinoma Treatment
study were not given credence during an Food and Drug
Administration review of the data [40], but they do provide
insight relevant for the design of future trials with immu-
notherapeutics, such as sipuleucel-T and other modalities.
In men with progressing mCRPC, treatment with an
autologous, genetically modiﬁed dendritic cell vaccine BPX‐
101 and its chemical activating agent AP1903 elicited meas-
urable clinical responses in some patients, including in those
who had visceral metastatic disease (Table 2) [41]. In addition,
data suggested a potential synergy between BPX‐101 and
docetaxel. Another cell-based vaccine under phase III evalua-
tion is DCVAC/Pa (www.clinicaltrialsregister.eu/ctr-search/
trial/2012-002814-38/HU). DCVAC/Pa is composed of den-
dritic cells pulsed with killed LNCap, a prostate cancer cell
line. Phase I/II data showed delayed PSA doubling time in all
patients, evidence of sustained T-cell responses against prostate
cancer antigens, and no signiﬁcant side effects [23].
3.2. Immunotherapies modulating T-cell function
Ipilimumab is an anti–CTLA-4 monoclonal antibody
approved for the treatment of metastatic melanoma.
CTLA-4 is an inhibitory immune checkpoint receptor that
acts to ﬁne-tune the immune response, preventing auto-
immunity. Several phase I and II clinical trials have
evaluated different doses, schedules, and combinations in
patients with mCRPC (Table 2). In preliminary trials,
decreases in PSA levels ofZ50% were observed with a
single dose of ipilimumab (3 mg/kg), ipilimumab mono-
therapy (3 mg/kg every 4 wk in chemotherapy-naïve
patients), and ipilimumab (0.5–10 mg/kg every 4 wk) in
combination with GM-CSF; the results also suggested thatipilimumab could be administered safely, supporting further
evaluation [24,26,29]. Data from a small trial using
ipilimumab plus docetaxel vs. ipilimumab alone did not
suggest that this combination improved the activity of
ipilimumab [29]. However, small trials using ipilimumab
in combination with ADT or RT showed encouraging
clinical activity, supporting further evaluation [30,31].
Combining ipilimumab with a vaccine to enhance costi-
mulation of the immune system has been evaluated using
PSA-TRICOM and GVAX. Findings showed that the combi-
nations were feasible [32,33]. Based on data to date, new trials
with ipilimumab alone and in combination are planned or
ongoing, including a phase III trial in treatment-naïve patients
(NCT01057810) (Table 3). Recent data from a phase III trial
of a single dose of RT followed by ipilimumab or placebo in
previously treated patients showed the primary end point, i.e.,
OS, was not met (ipilimumab vs. placebo, 11.2 vs. 10.0 mo,
respectively; hazard ratio ¼ 0.85; P ¼ 0.053); however,
there was an improvement in PFS and PSA responses. The
safety proﬁle was consistent with that found in previous
ipilimumab studies. Findings from a post hoc, exploratory
subgroup analysis showed that ipilimumab did improve OS in
patients with a better prognostic proﬁle (no visceral meta-
stases, alkaline phosphataseo1.5 times the upper limit of the
normal range, and hemoglobinZ11 g/dl), supporting further
evaluation of ipilimumab in patients with a lower disease
burden (median OS: ipilimumab [n ¼ 146] vs. placebo [n ¼
142], 22.7 vs. 15.8 mo, respectively) [25]. Another phase III
trial has completed enrolling patients with less advanced,
chemotherapy-naïve CRPC (Table 3).
Nivolumab is an anti–PD-1 antibody that has been
evaluated in a range of solid tumors [42]. Although there
were objective responses in patients with other solid tumors,
there were no responses in patients with CRPC, although
only 17 patients were enrolled. Given the PD-1þ status of
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cancer [14], it may be appropriate to investigate PD-1
blockade alone and in combination with other therapies,
perhaps for patients with a high level of PD-1þ T cells in
their tissue specimen. CT-011, another anti–PD-1 antibody,
is being evaluated in a phase II trial in combination with
sipuleucel-T and low-dose cyclophosphamide (NCT0142
0965). Another T-cell–targeted agent AMG-212, a T-cell–
engaging, bispeciﬁc antibody, is in early development
for treatment of prostate cancer (NCT01723475;
Table 3).
3.3. Other immunomodulatory agents
In addition to the therapies discussed, tasquinimod, a
quinolone-3-carboxamide, may also have an immunomo-
dulatory effect. A molecular target for tasquinimod is
S100A9, an immunomodulatory protein expressed on
myeloid-derived suppressor cells. In a phase II trial, in
patients with minimally symptomatic mCRPC, tasquinimod
signiﬁcantly slowed progression and improved PFS (6-mo
progression-free proportions were 69% with tasqui-
nimod vs. 37% in placebo, Po 0.001; Table 2). Adverse
events included gastrointestinal disorders, fatigue, and
musculoskeletal pain [28]. A phase III trial is ongoing
(Table 3).
Lenalidomide is an oral thalidomide analogue that has
antiangiogenic, anti-inﬂammatory, and immunomodulatory
effects; it is under evaluation alone and in combination for
treatment of prostate cancer [43]. Findings from studies
evaluating lenalidomide alone in mCRPC showed evidence
of clinical activity (Table 2) [43]. Recent data from a phase
II trial in patients with chemotherapy-naïve CRPC showed a
PSA level decline in 13 of 27 evaluable patients (48%),
with serious adverse events in 44% of patients [34]. Modest
antitumor activity was also reported from a phase II trial
using lenalidomide plus GM-CSF in patients with CRPC;
81% of the 31 evaluable patients had a PSA decline,
and 4 had a decline Z50%. Grade 3 or 4 toxicities occurred
in 22% of patients [35]. However, in a phase III trial
(MAINSAIL), lenalidomide in combination with doc-
etaxel and prednisone failed to improve survival and
increased toxicity in patients with CRPC [44]. Despite the
poor outcome with lenalidomide in combination with
chemotherapy, phase I and II trials are ongoing to further
evaluate the potential of lenalidomide alone and in combi-
nation with chemotherapy or targeted therapies or both
(Table 3).4. Integrating immunotherapy into clinical practice
Current evidence demonstrates the potential for immu-
notherapy to augment advanced prostate cancer treatment.
However, the most efﬁcient integration of this approach into
clinical practice requires further investigation.4.1. Optimal use of immunotherapies
A fundamental question arises regarding the optimal
timing of immunotherapy. Because OS is the regulatory end
point for registrational approval, immunotherapies, as with
most new cancer therapies, are initially evaluated in
previously treated patients with signiﬁcantly advanced
disease. Nonetheless, the integrity and functional status of
the immune system at the time of therapy is an extremely
important consideration, as it may be suppressed by
previous treatment (e.g., chemotherapy or corticosteroids),
extent of tumor burden, and age and associated comorbid-
ities. Hence, immunotherapies may be most effective when
administered earlier in the disease paradigm when tumor
burden is low (e.g., after debulking therapy).
In support of earlier treatment, a post hoc analysis of data
from a trial using sipuleucel-T in patients with symptomatic
or minimally symptomatic mCRPC suggested that patients
with a lower serum PSA level, and presumably lower
disease burden, derived a larger survival beneﬁt when
compared with those with higher PSA levels and greater
disease burden [45]. Phase III data of ipilimumab in
advanced mCRPC suggest that ipilimumab may be more
active in patients with a lower tumor burden (i.e., no
visceral metastases) [25]. Interestingly, a preclinical study
has shown an advantage of administering immunotherapy
before castration [46], and in a clinical trial, sipuleucel-T
was shown to increase PSA doubling time, consistent with a
biological effect, in patients with hormone-sensitive disease
[47]. These data support further investigation of immuno-
therapies in earlier stages of prostate cancer, perhaps as
early as the initial hormone-sensitive therapy setting.
Another important consideration is whether the activity of
an immunotherapy can be improved by using it in combina-
tion or sequentially with another immunotherapy, ADT, or
cytotoxic agents such as chemotherapy and RT. The
combination of immunotherapy with ADT is being evaluated
in several trials, and initial data are encouraging (Tables 2
and 3). In patients receiving ADT, there is evidence of
persistent changes in the adaptive immune response and T-
cell inﬁltration into the prostate, providing rationale for
combining with immunotherapy [48,49]. Preliminary data
from patients treated with sipuleucel-T in concurrent or
sequential combination with enzalutamide support the poten-
tial of this combination. In 1 case, a patient with rising PSA
response on treatment with enzalutamide received sipuleucel-
T in addition to enzalutamide; the combination resulted in a
complete PSA response, and the timing of the response
supported an immune mechanism [50]. The mechanism of
action may involve the release of secondary antigens that
prime subsequent immune response (antigen spread), as
reported recently with sipuleucel-T [51]. Initial data from
another trial evaluating sipuleucel-T given concurrently with
or before enzalutamide showed that the concurrent approach
is feasible and achieves an immunological prime boost [52].
Data from a study of patients who were given sipuleucel-T
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including a case of radiographic full regression of metastatic
lesions in the lung, bones, and lymph nodes [53]. Data from
a trial using sipuleucel-T and abiraterone also suggest that
this type of combination approach is feasible [54].
Combining immunotherapies with chemotherapy may also
be effective, as some cytotoxic agents can stimulate the
immune system by either inducing the immunogenic death of
tumor cells or engaging immune effector mechanisms [55]. In
particular, platinum-based chemotherapies can enhance the
immunostimulatory potential of dendritic cells and decrease
the immunosuppressive capacity of tumor cells [56]. How-
ever, experience shows that the choice of chemotherapy, dose,
and scheduling of the agents are all key, unresolved factors.
Scheduling may also be an important consideration for RT,
which alone has been shown to stimulate the immune system.
In transgenic mice that spontaneously develop prostate
cancer, the combination of immunotherapy and RT was
shown to result in antitumor T-cell activation, but the effect
was observed when immunotherapy was given 3 to 5 weeks
after RT and not earlier or later [57].
There is a clear rationale for combining immunotherapies
that target different components of the immune system, and
several trials are in progress (Table 3). Data from a phase I
trial showed that ipilimumab in combination with GM-CSF
for mCRPC induced clinical responses, warranting further
evaluation [26]. One of the most promising approaches is the
combination of immune checkpoint inhibitors, given the
distinct roles that immune checkpoint molecules play in
immune regulatory pathways. In a clinical study of patients
with advanced melanoma, the combination of ipilimumab
and nivolumab produced rapid and deep tumor responses that
appeared to be greater than that with either agent alone [58].
Clinical activity was observed both when the agents were
given concurrently and when patients who progressed on
treatment with ipilimumab subsequently received nivolumab.
The studies with ipilimumab and nivolumab in combi-
nation in advanced melanoma suggest the potential use of
these agents in combination or in sequence, and similar
studies are ongoing in other tumor types. However, the
concurrent administration of immunotherapies and other
types of agents may be limited by toxicities, as highlighted
by studies with molecularly targeted agents. For example, in
a phase I study of concurrent ipilimumab and vemurafenib
in BRAF-mutant advanced melanoma, dose-limiting toxic-
ities in the liver were observed, which caused patient
enrollment to be stopped [59]. Overall, the results of these
studies highlight the importance of carefully optimizing
treatment regimens with immunotherapies to minimize
patient risk while maximizing beneﬁt.
4.2. Response patterns and safety proﬁle
The collective experience with immunotherapies in the
treatment of cancer has revealed that they can produce
different response patterns and have a safety proﬁle that isdistinct from other therapies. Because immunotherapies
produce antitumor effects by inducing or enhancing
immune responses, such effects can be delayed and may
manifest as a gradual reduction in tumor growth, ultimately
resulting in prolonged OS that is not necessarily accom-
panied by objective tumor responses. For example, studies
of ipilimumab monotherapy in advanced melanoma have
shown that some tumor responses characterized as “pro-
gressive disease” by the standard response criteria may
actually be responses to treatment [60]. These “unconven-
tional” responses include the growth of existing, target
lesions before a response occurs (resulting initially in an
apparent increase in total tumor burden) and the develop-
ment of new lesions while others are responding (“mixed
responses”). Thus, in some patients who ultimately beneﬁt
from immunotherapy, the disease may progress before
antitumor effects are detected.
These unconventional response patterns are not observed
with cytotoxic agents and may reﬂect the time taken to build
antitumor immunity in patients treated with immunotherapy.
This may also be reﬂected in the delayed separation of
Kaplan-Meier survival curves observed in immunotherapy
trials (e.g., sipuleucel-T in mCRPC and ipilimumab in
advanced melanoma) [60]. Contrary to immunotherapies,
cytotoxic agents (chemotherapy and RT) elicit their effects
directly on tumor cells and cause a rapid reduction in tumor
volume in responding patients. These rapid effects can
improve PFS but are not always accompanied by an OS
beneﬁt. Conversely, immunotherapies may prolong OS
without an effect on measures of tumor response [60,61].
This can present a challenge to clinicians evaluating the
efﬁcacy of immunotherapies in individual patients, and it
may explain why PSA-TRICOM and sipuleucel-T trials in
prostate cancer demonstrated an improvement in OS but not
improved PFS or PSA responses [4,16,61].
The safety proﬁle of immunotherapies likely also reﬂects
their unique mechanisms of action. For example, with
ipilimumab, adverse events consistent with enhanced
immune activity are the most common drug-related toxic-
ities observed in patients [24–26]. These have been
described as “immune-related adverse events,” as they are
inﬂammatory in nature and consistent with immune phe-
nomena. Although immune-related adverse events can be
severe and life threatening, most are manageable when
treatment guidelines are followed, which include vigilant
patient follow-up and the use of corticosteroids. Thus, the
recognition of different response patterns and safety pro-
ﬁles, along with their appropriate management, are keys to
the successful use of immunotherapies in prostate cancer.
4.3. Potential immune-based predictive and prognostic
biomarkers
As discussed in the previous section, one of the
challenges in the development of immunotherapies is the
accurate assessment of clinical beneﬁt, given the potential
Table 5
Potential immune-based biomarkers in cancer [51,62–66]
Types of candidate biomarkers under evaluation
Immune-gene signatures and genetic proﬁles [62,63]
Parameters related to the interaction of the immune system and tumor
Immune cell populations including TILs, e.g., ALC [64]
Antibody or T-cell responses to cancer antigens (e.g., NY-ESO-1 [65],
KRAS, and PSA) [51]
Soluble factors (e.g., ICOS and IDO) [64,66]
Cell-signalling molecules, including T-cell checkpoint pathways (e.g., PD-
L1) [66]
ALC ¼ absolute lymphocyte count; ICOS ¼ inducible T-cell
costimulator; IDO ¼ indoleamine 2,3-dioxygenase; PD-L1 ¼ pro-
grammed death ligand-1; TILs ¼ tumor-inﬁltrating lymphocytes.
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challenge is the identiﬁcation of patients who are most
likely to beneﬁt from treatment and, in particular, to
experience a durable survival beneﬁt. Addressing both will
enable the optimal use and integration of immunotherapies
into the mCRPC treatment paradigm. Because of the
different patterns of clinical activity that can be associated
with immunotherapies, using predictive, prognostic, phar-
macodynamic, or surrogate biomarkers of activity may
enable a better assessment of clinical beneﬁt. Such markers
could aid in decision making regarding when to stop or
change therapy, something that is becoming increasingly
relevant with the number of new drugs. This is an area of
active investigation, with potential biomarker candidates
being identiﬁed, which ultimately have to be validated in
prospective studies. An overview of the key areas under
investigation for immune-based biomarkers in cancer is
provided in Table 5 [51,62–66].
Some proposed biomarkers for prostate cancer include
absolute lymphocyte count, T-cell activation and differ-
entiation (e.g., expression of PD-1, CTLA-4, forkhead box
P3, and inducible T-cell costimulator), and T-cell activity
(e.g., interferon-γ secretion, cytotoxicity, and proliferation).
Analysis of data with sipuleucel-T showed that markers of
an antigen-speciﬁc immune response (APC numbers, APC
activation [CD54 up-regulation], and total nucleated cell
numbers) correlated with OS, demonstrating immune acti-
vation as a mechanism of action for sipuleucel-T and also as
potential biomarkers [67,68]. In a trial using ipilimumab
and GVAX, high pretreatment frequencies of CD4þ/CTLA-
4þ, CD4þ/PD-1þ, or differentiated (i.e., nonnaïve) CD8 T
cells, or low pretreatment frequencies of differentiated CD4
or Tregs, were associated with signiﬁcantly prolonged OS
[67]. Finally, in patients with prostate cancer, data show
that a gene signature associated with an adaptive immune
response is correlated with a good prognosis [69].5. Conclusions
It is evident that prostate cancer has the potential to elicit
immune responses, and clinical data have proven theprinciple that immune modulation can prolong survival
[4]. However, the development and evaluation of immuno-
therapies for prostate cancer is in its infancy; perhaps,
immunotherapies may be most effective when used earlier
in, or throughout, the course of disease or with a combi-
nation that is yet to be discovered and schedule of several
agents with different, complimentary mechanisms of action.
Another important consideration for immunotherapy is that
development of an antitumor immune response is likely to
be effective irrespective of androgen receptor status [47].
There is also the possibility of identifying patients who
are most likely to beneﬁt from therapy. Most intriguing is
the possibility of identifying patients with high-risk, local-
ized prostate cancer, screening them for markers indicative
of a pre-existing antitumor immune response, and treating
them with immunotherapy in a neoadjuvant or adjuvant
setting. There is currently substantial evidence that immu-
notherapy may be of beneﬁt to patients with prostate cancer,
either in combination or in sequence with newer agents, and
at different disease stages. The continued evaluation of
immunotherapy for the treatment of prostate cancer engen-
ders ongoing future promise.References
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